Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib second-line study in advanced EGFR wild-type non-squamous non-small cell lung cancer
ChiCTR1800020105Phase 4Completed
- Sponsor
- General Hospital of Eastern Military Command
- Start
- Jul 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and docetaxel in non-small cell lung cancer (NSCLC), sponsored by General Hospital of Eastern Military Command. Primary endpoint: progression-free survival. Started Jul 2016; status: completed.
02
Drugs
Rivoceranibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1800020105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020105.